Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
What dose of prednisone do you prefer when treating CRPC vs CSPC with abiraterone?
Would you use reduced dose in diabetics?
Related Questions
How can we symptomatically manage dizziness or risk of fall in older patients on enzalutamide ?
How would you treat a patient presenting with de novo metastatic prostate cancer and baseline low testosterone?
Will prior novel hormonal therapy affect when/how you use olaparib plus abiraterone for patients with BRCA-mutated metastatic castration resistant prostate cancer?
How do you interpret PSMA/PET with focal prostate activity after XRT currently on ADT with stable PSA?
What techniques do you use to distinguish malignant from non-malignant (eg BPH etc) causes of PSA rise in patients with non-metastatic prostate cancer and a rising PSA in spite of ADT?
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
Is there adequate evidence for the use of PARPi in combination with ARSI for BRCA+/HRR mutated mCRPC as compared to sequential therapy?
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
How does the presence of PSMA negative lesions in a patient with mCRPC affect your decision to treat with Lutetium (177Lu) vipivotide tetraxetan?
Would you treat the prostate in a patient with widely metastatic disease who has CR to all metastatic sites after systemic therapy or ADT?
